BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).

Clinical trial NCT03227263 · COMPLETED

Trial details

NCT number: NCT03227263
Sponsor: Hospices Civils de Lyon
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Rendu Osler Disease Telangiectasia, Hereditary Hemorrhagic

Start date: 2017-09-28
Primary completion: 2020-05-15
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.